1632 EFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Confirmation No.: 9066

VALLANCE et al.

Atty. Ref.: 117-358

Appln. No. 09/889,733

Group Art Unit: 1632

Filed: September 14, 2001

Examiner: S.D. Priebe

FOR: DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED)

RESUBMISSION OF RESPONSE TO RESTRICTION REQUIREMENT

May 21, 2004

MS Amendment

U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The undersigned was contacted by Examiner Priebe, who explained that he had not received a response to his Office Action. Therefore, attached herewith is a copy of the Response to Restriction Requirement and an Information Disclosure Statement (IDS) filed February 26, 2004, along with a copy of the USPTO stamped postcard receipt.

If the documents submitted with the IDS have been lost by the USPTO, the Examiner is invited to contact the Applicants so additional copies can be provided.

Entry and consideration of the Response are respectfully requested. Please contact the undersigned if any further information is required.

Respectfully submitted,

NIXON & MANDERHYE P.C.

By:

Gark B. Tankawa Reg. No. 43,180

1100 North Glebe Road, 8th Floor

Arlington, VA 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100



Serial No.: 09/889,733

Atty: Gary R. Tanigawa Inventor/s: VALLANCE et al Date: February 26, 2004

C#/M#: 117-358

FEB 2 6 200

Title: DIMETHYLARGININE

DIMETHYLAMINOHYDROLASES (AS AMENDED)

RESPONSE TO RESTRICTION REQUIREMENT

\$ Fee (Check) - Pre-Bill

\$1480.00 Fee (Check) - Non Pre Bill P

\$1480.00 Total Fee Enclosed

INFORMATION DISCLOSURE

STATEMENT WITH FORM PTO-1449 AND REFERENCES

NUTED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Atty Dkt. 117-358 M#

C#

VALLANCE et al

Serial No. 09/889,733

Filed: September 14, 2001

Examiner: S.D. Priebe

Date: February 26, 2004

1632

DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (AS AMENDED)

C/A.U.

Commissioner for Patents .P.O. Box 1450 Alexandria, VA 22313-1450

·Sir:

RESPONSE TO RESTRICTION REQUIREMENT

This is a response/amendment/letter in the above-identified application and includes an attachment which is hereby

	y other
\$	0.00
\$	0.00
\$	0.00
\$	1,480.0
\$	0.00
\$	0.00
\$	1480.00
·\$	0.00
\$	0.00
\$	C:.00
	\$ \$ \$ \$ \$ \$ \$

Other: INFORMATION DISCLOSURE STATEMENT; PTO FORM-1449 AND REFERENCES

TOTAL FEE ENCLOSED \$ 1480.00

The Commissioner is hereby authorized to charge any <u>deficiency</u>, or credit any overpayment, in the fee(s) filed, or asserted to be filed, or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Account No. 14-1140. A duplicate copy of this sheet is attached.

1100 North Glebe Road, 8th Floor Arlington, Virginia 22201-4714 Telephone: (703) 816-4000 Facsimile: (703) 816-4100

GRT:ap

NIXON & VANDERHYE P.C.

By Atty: Gary R. Tanigawa, Reg. No. 43,180

Signature:



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

VALLANCE et al.

Appln. No. 09/889,733

Filed: September 14, 2001

inca. September 14, 200

Confirmation No.: 9066

Atty. Ref.: 117-358

Group Art Unit: 1632

Examiner: S.D. Priebe

FOR: HUMAN DIMETHYLARGININE DIMETHYLAMINOHYDROLASES (as amended)

RESPONSE TO RESTRICTION REQUIREMENT

February 26, 2004

U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450



Sir:

In response to the pending Office Action (Paper No. 092203) mailed September 26, 2003, entry and consideration of the following amendments and remarks are respectfully requested.

Amended portions of the **specification** are presented on page 2.

A priority statement is added.

The Abstract of the Disclosure is attached.

The claims are presented on pages 3-9.

Claims 46, 48-52, 64 and 66-67 are amended.

Claims 54-63 and 68-70 are canceled without prejudice or disclaimer.

Claims 71-82 are added.

Remarks begin on page 10.